Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

BACKGROUND: Tumour necrosis factor inhibitors (TNFi) are effective in the treatment of patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). However, these drugs come with some disadvantages such as adverse events, practical burden for patien...

Full description

Saved in:

Bibliographic Details
Published in:	Trials
Main Authors:	Michielsens, Celia A. J., Boers, Nadine, den Broeder, Nathan, Wenink, Mark H., van der Maas, Aatke, Mahler, Elien A. M., Mulder, Michelle L. M., van der Heijde, Désirée, van den Hoogen, Frank H. J., Verhoef, Lise M., den Broeder, Alfons A.
Format:	Artigo
Language:	Inglês
Published:	BioMed Central 2020
Subjects:	Study Protocol
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6964104/ https://ncbi.nlm.nih.gov/pubmed/31941544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-019-4000-5
Tags:	Add Tag No Tags, Be the first to tag this record!

Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

Similar Items